PAA PharmAust Ltd
- 0.190
- 0.0000.00%
PharmAust Ltd News
PharmAust Files Orphan Medicinal Product Designation for Sclerosis Treatment Following Regulatory Guidance
PharmAust Ltd: Appendix 4E and 2024 Annual Report
PharmAust Raises AU$7.8 Million via Share Placement
PharmAust (ASX:PAA) Shareholders Have Earned a 21% CAGR Over the Last Five Years
PharmAust Awarded SME Status in Europe, Further Promoting MND Treatment
PharmAust to Raise AU$10 Million in Placement; to Open Share Purchase Plan; Shares Fall 8%
PharmAust's Breakthrough MND/ALS Study Showcased at Major European Medical Conference
PharmAust Appoints Experienced US-based Pharma Executive to Board of Directors
Guess Which ASX Healthcare Stock Just Rocketed 20% on a 'Significant Milestone'
PharmAust Encouraged by Positive Monepantel Survival Rate Assessment
Stocks of the Hour: Calmer Co International, PharmAust, Magnum Mining & Exploration
PharmAust Solidifies Leadership Team Ahead of Key Stage 2/3 MPL Study
PharmAust Reappoints MD and Resets Its Sights on MND Battle
PharmAust Set to Transform MND Therapy Landscape as Monepantel Receives FDA Orphan Drug Designation
PharmAust Appoints Nonexecutive Chair; Shares Up 3%
Stocks of the Hour: PharmAust, Impact Minerals, Peregrine Gold
PharmAust Obtains Orphan Drug Designation for Monepantel; Shares Up 5%
Pharmaust Appoints Interim Chair, Managing Director; Shares Fall 16%
PharmAust to Build on Laboratory Success With Management Changes
PharmAust Gears for Major Clinical Milestones in 2024, Following Strong Start and FDA Feedback
Analysis
Price Target
No Data
No Data